title: Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs.
abstract: Mitomycin C (MMC) is a commonly used and extensively studied chemotherapeutic agent requiring biological reduction for activity. Damage to nuclear DNA is thought to be its primary mechanism of cell death. Due to a lack of evidence for significant MMC activation in the nucleus and for in vivo studies demonstrating the formation of MMC-DNA adducts, we chose to investigate alternative nucleic acid targets. Real-time reverse transcription-PCR was used to determine changes in mitochondrial gene expression induced by MMC treatment. Although no consistent effects on mitochondrial mRNA expression were observed, complementary results from reverse transcription-PCR experiments and gel-shift and binding assays demonstrated that MMC rapidly decreased the transcript levels of 18S ribosomal RNA in a concentration-dependent manner. Under hypoxic conditions, transcript levels of 18S rRNA decreased by 1.5-fold compared with untreated controls within 30 min. Recovery to base line required several hours, indicating that de novo synthesis of 18S was necessary. Addition of MMC to an in vitro translation reaction significantly decreased protein production in the cell-free system. Functional assays performed using a luciferase reporter construct in vivo determined that protein translation was inhibited, further confirming this mechanism of toxicity. The interaction of MMC with ribosomal RNA and subsequent inhibition of protein translation is consistent with mechanisms proposed for other natural compounds.
authors.affiliation: Department of Nutrition, University of Nevada, Reno, Nevada 89557, USA.
authors.forename: Ryan G
authors.initials: RG
authors.lastname: Snodgrass
authors.forename: Abby C
authors.initials: AC
authors.lastname: Collier
authors.forename: Amy E
authors.initials: AE
authors.lastname: Coon
authors.forename: Chris A
authors.initials: CA
authors.lastname: Pritsos
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001667:Binding, Competitive; D045744:Cell Line, Tumor; D002474:Cell-Free System; D018736:DNA Adducts / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016685:Mitomycin / Q000378:metabolism* / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012335:RNA, Ribosomal / Q000378:metabolism*; D012337:RNA, Ribosomal, 18S / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D018736:DNA Adducts; D012333:RNA, Messenger; D012335:RNA, Ribosomal; D012337:RNA, Ribosomal, 18S; D016685:Mitomycin